{"product_id":"hologic-bcg-matrix","title":"Hologic Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCurious where Hologic’s product lines really sit—Stars, Cash Cows, Dogs, or Question Marks? This snapshot teases the picture; buy the full BCG Matrix to get quadrant-by-quadrant placement, data-backed recommendations, and strategic moves you can act on. You’ll get a ready-to-present Word report plus an Excel summary so you can rework numbers and make decisions fast. Purchase now and skip the legwork—get clarity and a roadmap to smarter allocation today.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePanther molecular diagnostics platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePanther sits in Stars: high market share and a rapidly expanding test menu keep utilization and pull-through rising as each new assay leverages the same installed base. Every added assay increases throughput and lab stickiness, offsetting heavy upfront cash burn from placements, service and field support. The flywheel economics justify continued investment to widen the menu and lock in clinical labs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenius 3D mammography (tomosynthesis)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGenius 3D mammography leads as global screening shifts from 2D to tomosynthesis—US DBT adoption reached about 80% by 2024, and Hologic holds roughly 60% share of the tomosynthesis screening market, driving high volumes and replacements. Clinical superiority and brand recognition convert to durable revenue as adoption matures. Sales require capital for systems (~$400–600k), training and service, but supported deployments win share and recurring cash.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAptima HPV \u0026amp; women’s STI assays\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAptima HPV and women’s STI assays sit in the Stars quadrant as screening mandates and rising testing intensity drive strong market growth, with global HPV testing market forecasts around $3–4 billion by mid-decade (2024 estimates). Panther workflow and peer-reviewed clinical data continue to reinforce share, shortening adoption cycles. High reagent pull-through makes promotion and access investments pay back quickly through recurring consumable revenue. Continue to invest in market access and guideline wins to sustain momentum.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBreast biopsy systems (Affirm, Brevera, Eviva)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProcedure growth tracks DBT\/tomo screening—DBT adoption reached about 75% in the US by 2023, driving an ~8% YoY rise in image-guided biopsy volumes (2023–24); Affirm, Brevera, Eviva capture downstream work and generate recurring high-value disposable revenue above the capital sale; success requires ongoing KOL engagement, training, and placement support while targeting centers upgrading to 3D workflows.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCategory: Stars\u003c\/li\u003e\n\u003cli\u003eDrivers: DBT adoption ~75% (2023), biopsy volumes +8% YoY\u003c\/li\u003e\n\u003cli\u003eModel: capital + high-margin disposables, KOL\/training-dependent\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovaSure \u0026amp; MyoSure surgical suite\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNovaSure and MyoSure form a Stars position as minimally invasive gynecologic procedures shift outpatient; ASC share of benign gynecologic procedures reached an estimated 55% in 2024, driving demand. Strong physician preference and installed technique know‑how sustain momentum, with NovaSure showing low‑double‑digit procedure growth and MyoSure mid‑teens growth in 2024. Continued account wins require education, access, and territory coverage; invest to expand indications and ASC penetration to capture a ~$600M+ US addressable market.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhysician preference: high — retention of installed base\u003c\/li\u003e\n\u003cli\u003e2024 growth: NovaSure low‑double digits; MyoSure mid‑teens\u003c\/li\u003e\n\u003cli\u003ePriority investments: education, territory coverage, ASC partnerships\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh stickiness platform, DBT ~60% lead, $3–4B HPV consumables, ASC-driven device growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: Panther platform drives high reagent pull‑through and stickiness; Genius 3D leads with ~60% tomosynthesis share as US DBT adoption ~80% (2024); Aptima HPV benefits from a $3–4B global market (mid‑decade) and strong consumable margins; NovaSure\/MyoSure growing low‑double to mid‑teens (2024) as ASC shift accelerates.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003eGrowth\u003c\/th\u003e\n\u003cth\u003eKey driver\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePanther\u003c\/td\u003e\n\u003ctd\u003eHigh pull‑through\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003eInstalled base, assays\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenius 3D\u003c\/td\u003e\n\u003ctd\u003e~60% tomosynthesis share\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eDBT adoption ~80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAptima\u003c\/td\u003e\n\u003ctd\u003eHPV market $3–4B\u003c\/td\u003e\n\u003ctd\u003eStrong\u003c\/td\u003e\n\u003ctd\u003eRecurring reagents\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNovaSure\/MyoSure\u003c\/td\u003e\n\u003ctd\u003eASC share ~55%\u003c\/td\u003e\n\u003ctd\u003eLow‑double to mid‑teens\u003c\/td\u003e\n\u003ctd\u003eOutpatient shift\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix for Hologic: strategic guidance on which product lines to invest, hold, or divest with quadrant-level risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page overview placing each Hologic business unit in a quadrant\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThinPrep Pap test \u0026amp; cytology franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThinPrep Pap test \u0026amp; cytology franchise holds a commanding share in a mature, guideline-driven cervical screening market; 2024 growth remained low (low single-digit) but volumes stayed steady. Predictable, high-margin consumables with modest sales expense produce significant free cash flow. Reliability and scale throw off cash—maintain quality and ops efficiency: milk, don’t overfeed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstalled-base service and consumables (breast imaging)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInstalled-base breast imaging is a cash cow: a large fleet on service contracts delivers steady parts and detector-swap revenue with low growth but high renewal and excellent gross margins. Minimal promotion is needed—focus is uptime, SLAs, and predictable consumable spend. Operational levers are route optimization, faster parts turns, and value-based pricing to extract incremental cash.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMature CT\/GC testing in developed markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMature CT\/GC testing in developed markets shows stable volumes (roughly flat year‑over‑year, ±1%) with entrenched lab workflows and high share—a classic maintenance play for Hologic. Reagent pull‑through is dependable and margin‑rich (gross margins often in the high‑60s), while US STI burden remains large (~1.7M chlamydia, ~700k gonorrhea cases in 2024 provisional CDC data). Protect contracts and tighten supply chains to defend recurring revenue and reagent attach rates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecimen imaging (Faxitron, Trident HD) replacement cycle\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eReplacement-driven demand for Faxitron and Trident HD is steady, backed by strong brand trust and entrenched lab workflows; competition is present but slow-moving, helping margins remain intact. Sales intensity is modest after footprint saturation; uptime guarantees and trade-in programs are pivotal to keep replacement cycles active. Hologic reported approximately $4.0B revenue in FY2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReplacement-led demand\u003c\/li\u003e\n\u003cli\u003eSlow-moving competition → margins hold\u003c\/li\u003e\n\u003cli\u003eModest post-install sales intensity\u003c\/li\u003e\n\u003cli\u003ePrioritize uptime and trade-ins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBreast biopsy disposables recurring stream\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBreast biopsy disposables form a procedure-linked, recurring revenue stream for Hologic tied to installed platforms, contributing to Hologic’s FY2024 revenue of about 4.0 billion and delivering predictable volume flows from routine diagnostic workflows.\u003c\/p\u003e\n\u003cp\u003eMarket growth is low overall, but favorable pricing and consumable mix sustain strong margins and reduce the need for heavy promotion once accounts convert; retention is driven by procedure dependence and installed base economics.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProcedure-linked recurring sales\u003c\/li\u003e\n\u003cli\u003eForecastable volume from installed base\u003c\/li\u003e\n\u003cli\u003eLow market growth, margin support from pricing\/mix\u003c\/li\u003e\n\u003cli\u003eMinimal promotion after account win\u003c\/li\u003e\n\u003cli\u003eStandardize kits\/logistics to widen contribution\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-margin consumables \u0026amp; services fuel steady cash; FY2024 ≈ \u003cstrong\u003e$4.0B\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThinPrep\/cytology: dominant, low-single-digit 2024 growth, steady volumes and high-margin consumables driving free cash flow. Installed-base breast imaging: large service fleet, high renewal, low growth, strong parts\/contract margins. CT\/GC reagents: stable volumes, high‑60s gross margins; CDC provisional 2024: ~1.7M chlamydia, ~700k gonorrhea; Hologic FY2024 revenue ≈ $4.0B.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003e2024 datapoints\u003c\/th\u003e\n\u003cth\u003eMargin\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eThinPrep\u003c\/td\u003e\n\u003ctd\u003eConsumables cash flow\u003c\/td\u003e\n\u003ctd\u003eLow‑single‑digit growth, steady volumes\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBreast imaging service\u003c\/td\u003e\n\u003ctd\u003eService\/parts recurring\u003c\/td\u003e\n\u003ctd\u003eLarge installed base, low growth\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCT\/GC reagents\u003c\/td\u003e\n\u003ctd\u003eReagent pull‑through\u003c\/td\u003e\n\u003ctd\u003eCDC: ~1.7M chlamydia, ~700k gonorrhea\u003c\/td\u003e\n\u003ctd\u003eHigh‑60s%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany\u003c\/td\u003e\n\u003ctd\u003eTotal\u003c\/td\u003e\n\u003ctd\u003eFY2024 revenue ≈ $4.0B\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Transparency, Always\u003c\/span\u003e\u003cbr\u003eHologic BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing here is the exact Hologic BCG Matrix report you'll receive after purchase. No watermarks, no demo placeholders—just the fully formatted, analysis-ready document. Once bought it lands in your inbox as an editable, print-ready file you can present or adapt immediately. No surprises, no extra steps—just plug it into your planning and go.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCOVID-19 molecular assays\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePandemic tailwinds are gone: global COVID-19 PCR testing volumes fell by over 90% from the 2020 peak to 2024, leaving Hologic’s SARS-CoV-2 assay sales a fraction of prior levels. Price pressure and inventory overhang have compressed margins, with per-test pricing down an estimated 60–80% versus peak pandemic rates. Maintaining capacity beyond base demand becomes a cash trap; returns are thin. Wind down to core respiratory panels or repurpose instruments to other molecular assays.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy 2D mammography systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy 2D mammography sits in a low-growth quadrant with ongoing share erosion to tomosynthesis as DBT became the majority modality in screening by 2024; unit sales and upgrade interest are waning. Support and parts costs remain material while upgrade inquiries decline, shrinking strategic upside. Recommend harvest service contracts where profitable and accelerate planned sunsetting of legacy lines to free R\u0026amp;D and capital. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkeletal health (bone densitometry)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs: Skeletal health (bone densitometry) is a niche veterinary segment with limited addressable market and slow replacement cycles (equipment lifespans often 7–10 years), showing muted demand in 2024. High price sensitivity and low volumes mean limited synergies with Hologic growth engines and negligible margin uplift. Cash neutral at best after overhead; consider divest, partner, or minimally maintain. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOlder cytology instruments and accessories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOlder cytology instruments and accessories sit in Dogs: an installed base with \u0026gt;60% units older than 7 years and utilization down ~8% YoY in 2024, driving service-cost creep while consumables mix shifts to newer platforms and disposables. Service gross margins have compressed ~200 basis points across 2023–24 as field support and parts demand outpace revenue from these SKUs. Little room for differentiation; accessories are increasingly commoditized and face channel price pressure. Consolidate SKUs and retire models deliberately to cut service spend and free R\u0026amp;D resources.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003estatus: Dog\u003c\/li\u003e\n\u003cli\u003einstalled base: \u0026gt;60% aged \u0026gt;7 yrs\u003c\/li\u003e\n\u003cli\u003eutilization change: -8% YoY (2024)\u003c\/li\u003e\n\u003cli\u003emargin impact: -200 bps (2023–24)\u003c\/li\u003e\n\u003cli\u003eaction: consolidate SKUs; phased retirements\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-core legacy accessories in breast centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNon-core legacy accessories in breast centers are small-volume, fragmented SKUs that tie up operations and inventory, dragging margins after support and compliance; Hologic reported approximately $4.3B revenue in FY2024, making these SKUs a strategic distraction from high-value core platforms—prune aggressively to free capacity and protect core margins.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSKU bloat: low volume, high handling\u003c\/li\u003e\n\u003cli\u003eMargin hit: post-support costs shrink returns\u003c\/li\u003e\n\u003cli\u003eStrategic drag: distracts R\u0026amp;D and sales\u003c\/li\u003e\n\u003cli\u003eAction: prune aggressively to free capacity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCull legacy 'dogs' - prune SKUs, retire products, divest to free R\u0026amp;D capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs: legacy low-growth assets (bone densitometry, older cytology, non-core accessories) show \u0026gt;60% installed base \u0026gt;7 yrs, utilization -8% YoY (2024) and service margins down ~200 bps; Hologic FY2024 revenue ~$4.3B makes these cash-neutral or cash-drains. Action: prune SKUs, phase retirements, divest or partner where scale absent to free R\u0026amp;D\/capital.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstalled base aged \u0026gt;7 yrs\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUtilization change\u003c\/td\u003e\n\u003ctd\u003e-8% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService margin impact\u003c\/td\u003e\n\u003ctd\u003e-200 bps\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCorporate revenue\u003c\/td\u003e\n\u003ctd\u003e$4.3B FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAI-enabled imaging (e.g., 3DQuorum, decision support)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAI-enabled imaging sits in the Question Marks quadrant: market interest is high (AI medical imaging CAGR ~36% to 2030) but share and standards remain unsettled; studies report AI can improve breast cancer detection ~8–12% and reduce read time ~20%.\u003c\/p\u003e\n\u003cp\u003eProof of outcomes, workflow fit and reimbursement are required; clinical validation and installs demand multimillion-dollar pilots and ongoing capital. Bet selectively where evidence shows faster reads and higher cancer yield.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePanther expansion in emerging markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePanther expansion in emerging markets faces growing testing demand—the molecular diagnostics market was estimated at ~$19B in 2024—yet fragmented funding and pricing pressure persist. Hologic holds low share in several EM regions today, so growth requires channel development, tender wins, and localized assay menus. Prioritize investments where reagent pull‑through delivers payback within 24 months. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVaginitis\/UTI and AMR-focused panels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eClinical need is rising: bacterial vaginosis affects ~29% of US reproductive-age women and UTIs account for ~10 million ambulatory visits annually; AMR caused an estimated 1.27 million deaths in 2019, underscoring demand for vaginitis\/UTI and AMR-focused panels. Menus are still shaping up; Hologic has early share but reimbursement remains uncertain in pockets. Development and market education entail high upfront costs. Double down if stewardship and guideline momentum firm up.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLOCalizer RFID lesion localization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLOCalizer sits as a Question Mark in Hologic’s BCG matrix: wireless localization is displacing wires, but competition is active and by 2024 FDA‑cleared alternatives include Savi Scout and Magseed. Adoption hinges on surgeon preference, peri‑op workflow integration, and availability of trained staff and capital for tag placement. Success requires procedural champions and bundled deals across the breast surgery ecosystem.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket status: multiple FDA‑cleared wireless players (2024)\u003c\/li\u003e\n\u003cli\u003eAdoption drivers: surgeon preference, OR workflow\u003c\/li\u003e\n\u003cli\u003eRequirements: training, capital, champions\u003c\/li\u003e\n\u003cli\u003eGo‑to‑market: bundle with breast imaging\/surgery services\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePeri-procedural workflow software and analytics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHospitals demand throughput and quality metrics but face tight budgets; peri-procedural workflow software currently has low share yet high attach potential to imaging and biopsy, with 3–6 month pilots in 2024 used to prove ROI. Successful pilots must demonstrate integrations with PACS\/EMR, measurable time-to-diagnosis reductions, and cost-per-case savings before scaling.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003elow share, high attach to imaging\/biopsy\u003c\/li\u003e\n\u003cli\u003erequires PACS\/EMR integration\u003c\/li\u003e\n\u003cli\u003e2024 pilots: 3–6 months to prove ROI\u003c\/li\u003e\n\u003cli\u003escale where shortens time-to-diagnosis\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAI imaging \u003cstrong\u003e36%\u003c\/strong\u003e CAGR — +8–12% detection, −20% read time\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAI imaging: high-growth (AI imaging CAGR ~36% to 2030), +8–12% cancer detection, −20% read time; needs outcomes, reimbursement. Panther: molecular market ~$19B (2024), low EM share; prioritize reagent pull‑through with ≤24‑month payback. LOCalizer: multiple FDA clears (Savi Scout, Magseed, 2024); surgeon champions required. Peri‑op software: 3–6 month pilots to prove ROI.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eOffering\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003eBarrier\u003c\/th\u003e\n\u003cth\u003eGT-M\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI imaging\u003c\/td\u003e\n\u003ctd\u003eCAGR ~36%\u003c\/td\u003e\n\u003ctd\u003eevidence\/reimb\u003c\/td\u003e\n\u003ctd\u003eselect pilots\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePanther\u003c\/td\u003e\n\u003ctd\u003e$19B market\u003c\/td\u003e\n\u003ctd\u003epricing\/channel\u003c\/td\u003e\n\u003ctd\u003elocalize assays\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLOCalizer\u003c\/td\u003e\n\u003ctd\u003eMultiple FDA\u003c\/td\u003e\n\u003ctd\u003esurgeon prefs\u003c\/td\u003e\n\u003ctd\u003ebundle sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeri‑op SW\u003c\/td\u003e\n\u003ctd\u003ePilot 3–6m\u003c\/td\u003e\n\u003ctd\u003eEMR integration\u003c\/td\u003e\n\u003ctd\u003eprove ROI\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58098193826140,"sku":"hologic-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/hologic-bcg-matrix.png?v=1781796846","url":"https:\/\/pestel-analysis.com\/products\/hologic-bcg-matrix","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}